背景：C-X-C 基序趋化因子配体 9 (CXCL9) 通过招募和激活免疫细胞在肿瘤免疫中发挥关键作用。然而，CXCL9表达与三阴性乳腺癌（TNBC）预后之间的关系尚不清楚。方法：我们研究了 TNBC 患者的 CXCL9 mRNA 表达、临床病理特征和预后。我们还使用计算图像分析来量化和评估 CXCL9 蛋白在肿瘤核心 (TC) 和浸润边缘 (IM) 中的分布。结果：与正常组织相比，TNBC 肿瘤中的 CXCL9 mRNA 表达显着较高 (p < 0.001)，并且与较小的肿瘤 (p = 0.022) 和早期阶段 (p = 0.033) 相关。在三个独立队列中，CXCL9 mRNA 高表达与总生存期 (OS) 的改善相关（所有 p < 0.05）。在另一项分析中，CXCL9 蛋白表达低与淋巴结转移增加相关（p = 0.018 和 p = 0.036）。 TC、IM 或两者中的高 CXCL9 蛋白表达与 OS 延长相关（所有 p < 0.001）。结论：CXCL9 在 mRNA 和蛋白质水平上的高表达与 TNBC 患者预后的改善相关。 TC 和/或 IM 中的 CXCL9 表达可能是一个独立的预后因素。版权所有 © 2024 曹、宋、吴、任、孙和梁。

Background: The C-X-C motif chemokine ligand 9 (CXCL9) plays a pivotal role in tumor immunity by recruiting and activating immune cells. However, the relationship between CXCL9 expression and prognosis in triple-negative breast cancer (TNBC) is unclear. Methods: We investigated CXCL9 mRNA expression, clinicopathological features, and prognosis in TNBC patients. We also used computational image analysis to quantify and assess the distribution of CXCL9 protein in the tumor core (TC) and invasive margin (IM). Results: CXCL9 mRNA expression was significantly higher in TNBC tumors compared to normal tissue (p < 0.001) and was associated with smaller tumors (p = 0.022) and earlier stages (p = 0.033). High CXCL9 mRNA expression was correlated with improved overall survival (OS) in three independent cohorts (all p < 0.05). In a separate analysis, low CXCL9 protein expression was associated with increased lymph node metastasis (p = 0.018 and p = 0.036). High CXCL9 protein expression in the TC, IM, or both was associated with prolonged OS (all p < 0.001). Conclusion: High CXCL9 expression, at both the mRNA and protein levels, is associated with improved prognosis in TNBC patients. CXCL9 expression in the TC and/or IM may be an independent prognostic factor.Copyright © 2024 Cao, Song, Wu, Ren, Sun and Liang.